ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 188,49
-0,63%
Dow Jones
39 869,38
-0,10%
DAX
18 738,81
-0,72%
Brent Oil
83,115
-0,11%
Bitcoin
65 299,76
0,09%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Halozyme Therapeutics Incorporated (HALO)

  7. Halozyme Therapeutics Incorporated (HALO) Actualités

HALO

Halozyme Therapeutics (HALO)

Halozyme Therapeutics Incorporated
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:HALO
DateHeureSourceTitreSymboleSociété
08/05/202414h30PR Newswire (US)Halozyme to Participate in Upcoming Investor ConferencesNASDAQ:HALOHalozyme Therapeutics Incorporated
07/05/202422h09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HALOHalozyme Therapeutics Incorporated
07/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HALOHalozyme Therapeutics Incorporated
07/05/202422h01PR Newswire (US)HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
25/04/202422h45PR Newswire (US)Mahesh Krishnan Elected to Halozyme's Board of DirectorsNASDAQ:HALOHalozyme Therapeutics Incorporated
23/04/202414h30PR Newswire (US)Halozyme to Report First Quarter 2024 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
04/03/202422h13Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:HALOHalozyme Therapeutics Incorporated
29/02/202400h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
28/02/202422h07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
20/02/202422h07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:HALOHalozyme Therapeutics Incorporated
20/02/202422h01PR Newswire (US)HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
12/02/202412h19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:HALOHalozyme Therapeutics Incorporated
08/02/202422h30PR Newswire (US)Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
29/01/202422h15PR Newswire (US)Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NASDAQ:HALOHalozyme Therapeutics Incorporated
18/01/202414h30PR Newswire (US)Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia GravisNASDAQ:HALOHalozyme Therapeutics Incorporated
16/01/202414h15PR Newswire (US)Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NASDAQ:HALOHalozyme Therapeutics Incorporated
16/01/202407h15PR Newswire (US)Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer TypesNASDAQ:HALOHalozyme Therapeutics Incorporated
12/01/202415h25PR Newswire (US)Halozyme to Host Investor Business Forum and Long-Term Outlook CallNASDAQ:HALOHalozyme Therapeutics Incorporated
27/11/202314h00PR Newswire (US)Halozyme to Present at Upcoming Investor ConferencesNASDAQ:HALOHalozyme Therapeutics Incorporated
16/11/202315h00PR Newswire (US)Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia GravisNASDAQ:HALOHalozyme Therapeutics Incorporated
06/11/202322h01PR Newswire (US)HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
06/11/202313h30PR Newswire (US)Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's DiseaseNASDAQ:HALOHalozyme Therapeutics Incorporated
30/10/202323h35PR Newswire (US)Halozyme To Report Third Quarter 2023 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
19/10/202313h15PR Newswire (US)Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell CarcinomaNASDAQ:HALOHalozyme Therapeutics Incorporated
16/10/202321h05PR Newswire (US)Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery ConferenceNASDAQ:HALOHalozyme Therapeutics Incorporated
16/10/202314h00PR Newswire (US)Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug DeliveryNASDAQ:HALOHalozyme Therapeutics Incorporated
29/08/202310h50PR Newswire (US)Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great BritainNASDAQ:HALOHalozyme Therapeutics Incorporated
08/08/202322h01PR Newswire (US)HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
25/07/202314h30PR Newswire (US)Halozyme To Report Second Quarter 2023 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
17/07/202307h15PR Newswire (US)Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:HALOHalozyme Therapeutics Incorporated
 Showing the most relevant articles for your search:NASDAQ:HALO

Dernières Valeurs Consultées

COIN
HERBUST
Herbalist Token
NASDAQ
GILT
Gilat Satellite Networks
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés